Basf Se Corporation

Merck Patent Gmbh

Ciba Specialty Chemicals Corporation

Novartis Ag

Nissan Chemical Industries Limited

Solvias Ag

Teva Pharmaceutical Industries Limited

Gruenenthal Gmbh

Ratiopharm Gmbh

Ciba Specialty Chemicals Corpation

Martin Szelagiewicz

Fritz Blatter

Rudolf Moser

Andreas Hafner

Viola Groehn

Andreas Burkhard

Ruth Boehni Stamm

Claudia Marcolli

Paul Adriaan Van Der Schaaf

Tobias Hintermann

Tiziana Chiodo

Beate Salvador

Marcus Vossen

Bernd Siebenhaar

Paul Van Der Schaaf

Urs Christoph Hofmeier

Robert Portmann

Walter Scherrer

Markus Ruettimann

Franz Schwarzenbach

Giuseppe Lapadula

Beat Freiermuth

Heinz Wolleb

Annemarie Wolleb

Kai-Uwe Schoening

Markus Von Raumer

Hans-Jörg Kirner

Eva Roedel

Ulrich Berens

Kai-Uwe Schöning

Hans Jürg Kirner

Martin Viertelhaus

Michael Gruss

Wolfgang Hell

Susan Margaret De Paul

Walter Weishaar

Jörg Berghausen

Eva Rödel

Joerg Berghausen

Brigitte Monika Cron-Eckhardt

Peter Koller

Regine Peter

The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.

Crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethyl ester, wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to amino acid ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and amino ethyl esters

Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, their use as pharmaceuticals, as well as processes of obtaining the same.

Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and l-leucine ethyl ester

The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to 4-(2-hydroxyethyl)-morpholine is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

Crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine

The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:1.51 to 1:2.5 and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.

Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid

The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.

The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising

Crystalline binary sodium salts of 5-methyl-(6S)-tetrahydrofolic acid with organic bases

Combinations of (3&#x3b2;)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acid are useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.

Solid form of abiraterone acetate

The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

Salts of dasatinib in amorphous form

The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.

Multicomponent crystalline system comprising nilotinib and selected co-crystal formers

The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

Salts of Dasatinib in crystalline form

Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(&#x2212;)-menthol. 

Multicomponent crystals comprising dasatinib and selected co-crystal formers

The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN: Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same. 

Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof

Growing community of inventors

Basel, Switzerland

Martin Szelagiewicz